Abstract
Exenatide extended-release for injectable suspension, BYDUREON® 2mg, an injectable glucagon-like peptide-1(GLP-1)receptor agonist, has been shown to improve glycemic control with positive effect on body weight in patients with type 2 diabetes. This long acting formulation contains exenatide encapsulated in microspheres of PLG. It is injected subcutaneously by patients once weekly, with no dose titration required. However, it was complicated to prepare for injection. Therefore, BYDUREON® 2mg Pen, a single-use, dual-chamber pen was developed to improve the convenience of exenatide once weekly delivery.
